Advertisement

Archives of Pharmacal Research

, Volume 22, Issue 6, pp 592–607 | Cite as

Effect of the aryl substituent on antitumor activity of 2-substituted-1,4-dihydroxy-9,10-anthraquinones and 2-substitutedanthracene-1,4,9,10-tetraones

  • Nguyen-Hai Nam
  • Guang-Zhu Jin
  • Mai Ngoc Tam
  • Byung-Zun Ahn
Research Articles Medicinal Chemistry

Abstract

2-(1-Aryl-1-hydroxymethyl)- and 2-aroyl-DHAQ derivatives (DHAQ, 1,4-dihydroxy-9,10-anthraquinone), and 2-(1-aryl-1-hydroxymethyl)-ATO derivatives (ATO, anthracene-1,4,9,10-tetraone) were synthesized and their antitumor activities were determined. 2-(1-Aryl-1-hydroxymethyl)-DHAQ derivatives showed a stronger cytotoxicity compared to the series of 2-(1-hydroxyalkyl)-1,4-dihydroxy-9,10-anthraquinone derivatives. It was suggested that the presence of aryl group at the side chain accelerated the bioreductive activation leading to cell death. 2-Aroyl-DHAQ derivatives, despite their higher electrophilicity, revealed smaller cytotoxicity and antitumor activity (expressed by T/C value) than 2-(1-aryl-1-hydroxymethyl)-DHAQ derivatives. Thus, no consistent relationship between the electronic effect on aromatic side chain and the cytotoxicity was observed. ATO series exhibited a higher antitumor activity (T/C, 125–218%), though their cytotoxicity was not further improved compared to that of 2-(1-aryl-1-hydroxymethyl)-1,4-dihydroxy-9,10-anthraquinones. They manifested no correlation between the cytotoxicity and the antitumor activity. In case of 2-[1-hydroxy-1-(4-propylphenyl)-methyl]-ATO, the most bioactive onein vivo among the same series, it showed an ED50 value of 10.2 mg/mL and a T/C value of 218%. It is assumed that the anthracene-1,4,9,10-tetraones after uptake into cellular tissues might be transformed to a cytotoxic metabolite(s).

Key words

1,4-dihydroxy-9,10-anthraquinone anthracene-1,4,9,10-tetraones antitumor activity structure-activity relationship 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References Cited

  1. Baik, K. U., Jung, S. H. and Ahn, B. Z. Recognition of Phar-macophore of ar-Turmerone for its anticancer Activity.Arch. Pharm. Res. 16, 254–256 (1993a).CrossRefGoogle Scholar
  2. Baik, K. U., Jung, S. H. and Ahn, B. Z Structure-Activity Relationship of ar-Turmerone Analogues.Arch. Pharm. Res. 16, 219 (1993b)Google Scholar
  3. Blanz, J., Mewes, K., Ehninger, G., Gebhardt, R., Zeller, K. P.,Drug. Metab. Dispos., 19, 871–880 (1991).PubMedGoogle Scholar
  4. Ehninger, G., Chuler, U., Proksch, B., Zeller, K. P., Blanz, J., Pharmacokinetics and metabolism of mitoxantrone. A review.Clin. Pharmacokinet., 18 365–38 (1990).PubMedCrossRefGoogle Scholar
  5. Jin, G. Z., Kim, Y., Ho, C. J., Sok, D. E., and Ahn, B. Z., 1,4,9,10-Anthraquinone Derivatives: Synthesis and Antitumor Activity.Arch. Pharm. Pharm. Med. Chem., 331, 380–384 (1998a).CrossRefGoogle Scholar
  6. Jin, G. Z., Song, G. Y., Zheng, S. G., Kim, Y., Sok, D. E., and Ahn, B. Z., 2-(1-Oxyalkyl)-1,4-dioxy-9,10-anthraquinones: Synthesis and Evaluation of antitumor Activity.Arch. Pharm. Res., 21(2), 208–206 (1998b).CrossRefGoogle Scholar
  7. Mewes, K., Blanz, J., Ehninger, G., Gebhardt, R., and Zeller, K. P., Cytochrome p-450-induced Cytotoxicity of Mitoxantrone by Formation of Electrophilic Intermediates.Cancer Res., 2093, 1, 5135–5142 (1993).Google Scholar
  8. National Cancer Institute Protocol, U. S. A. (1972)Google Scholar
  9. Song, G. Y., Zheng, X. G., Kim, Y., You, Y. J., Sok, D. E., and Ahn, B. Z., Naphthazarin derivatives (II): Formation of glutathione conjugate inhibition of DNA topoisomerase-I and cytotoxicity.Bioorg. Chem. Med. Chem. Letter 9, 2407–2412 (1999).CrossRefGoogle Scholar
  10. Song, G. Y., Kim, Y., Zheng, X, G., You, Y. J., Cho, H., Chung, J. H., Sok, D. E. and Ahn, B. Z. Naphthazarin Derivatives (IV). Synthesis, Inhibition of DNA topoisomerase-I and Cytotoxicity of 2- or 6-Acyl-5,8-dimethoxy-1,4-naphthoquinones.European J. Med. Chem. (1999) in press.Google Scholar
  11. Thayer, P. S., Himnelfarb, L. A., Watt, G. L.,Cancer Chemotherapy 2, 1–25 (1971).Google Scholar

Copyright information

© The Pharmaceutical Society of Korea 1999

Authors and Affiliations

  • Nguyen-Hai Nam
    • 1
  • Guang-Zhu Jin
    • 2
  • Mai Ngoc Tam
    • 3
  • Byung-Zun Ahn
    • 1
  1. 1.College of PharmacyChungnam National UniversityTaejonKorea
  2. 2.College of PharmacyYanbiam UniversityYanji, JilinChina
  3. 3.Institute of ChemistryNational Centre of Natural Science and TechnologyHa NoiViet Nam

Personalised recommendations